Spotlight On... Valeant sets March 15 release for delayed Q4 results; Most doctors ready to prescribe biosims if discounts hit 25%; Market watchers piqued by Valeant CEO's one-on-ones with bullish analysts; and more...

Valeant ($VRX) investors eager for answers will get some on March 15, the company promised. That's when it now intends to release preliminary quarterly results--which it delayed last week for a variety of reasons, including pneumonia-stricken CEO J. Michael Pearson's comeback--and it'll hold a conference call that day, too. Release | More

@FiercePharma: Heska's topsy-turvy year ends on a high note as earnings beat estimates. More from FierceAnimalHealth | Follow @FiercePharma

@CarlyHFierce: Victoza comes up big for Novo with key heart-risk lowering data. More | Follow @CarlyHFierce

> In some statistical evidence for common sense, a physician survey found that doctors would be most likely to prescribe biosimilar drugs at bigger discounts. Report

> Valeant ($VRX) CEO Michael Pearson's one-on-one calls with handpicked analysts last week raised eyebrows among other analysts and investors who are looking for more transparency at the embattled company. Report

> New Jersey's Alvogen has agreed to buy generic drugmaker County Line Pharmaceuticals. Release

> Accord Healthcare is bringing up to 100 new jobs to a Newcastle, U.K. site where Sanofi ($SNY) ceased operations last year. More

Medical Device News

@FierceMedDev: ICYMI: Siemens Healthcare CEO: restructured unit 'hungry' for M&A deals. Article | Follow @FierceMedDev

@EmilyWFierce: UPDATED: AZ stokes $45B sales hopes with expanded approval for breast cancer drug Faslodex. More | Follow @EmilyWFierce

> FDA nod for smart contact lens that continuously monitors eye pressure changes in glaucoma. More

> Next up on Thermo Fisher's to-do list? Some serious M&A: Analyst. Report

> Senators butt heads over proposed device (and drug) industry regulatory overhaul. Article

Biotech News

@FierceBiotech: Celldex's cancer vaccine Rintega implodes in glioblastoma PhIII. News | Follow @FierceBiotech

@JohnCFierce: AbbVie hands over $595M upfront to partner with Boehringer on PhIII psoriasis drug. Report | Follow @JohnCFierce

> Bristol-Myers prints a pair of 'Golden Tickets' for Cambridge biotech startups. Report

> Europe takes a page from the FDA with new speedy approval program. Story

> Aimmune's peanut allergy drug clears Phase II on the way to a pivotal test. Article

Pharma Marketing News

> With Allergan's Kybella campaign, Khloé Kardashian follows sister Kim into pharma land. Report

> New privacy-friendly partnership taps consumer data to help pharma target mobile marketing. Item

> J&J, AbbVie swell Imbruvica patient pool with first-line FDA nod in CLL. More

> DTC challenges mount as senators roll out bill to yank tax deduction. Story

> New privacy-friendly partnership taps consumer data to help pharma target mobile marketing. Article

Animal Health News

> Kindred projects increased spending as it preps for first commercial product. Item

> VCA adds 56 veterinary clinics by snapping up $344M stake in Las Vegas chain. Report

> Heska's topsy-turvy year ends on a high note as record earnings beat estimates. More

> Under pressure from activists, In-N-Out Burger jumps on antibiotic-free bandwagon. Story

> Zoetis launches first genomic test for predicting common diseases in Holsteins. Article

Biotech IT News

> Bristol-Myers signs deal to use Veeva tools for regulatory information. News

> U.K. firms team up to develop mental health-tracking wearable devices. Report

> GSK extends business process analytics contract to 2020. Story

> George Church's Veritas starts $999 whole-genome sequencing service. Item

> IPhone-based Parkinson's study shares 6 months of data on 9,500 participants. Article

And Finally... A study has identified a link between an ADHD med and diminished bone health in kids. More

Suggested Articles

Dupixent has been posting strong sales growth for Sanofi, and now the drugmaker has a third FDA indication to keep the momentum going.

Novartis has found itself caught up in a controversy about ingredients shipped to Syria that critics say could have been used to make sarin gas. 

AbbVie made a major splash Tuesday with its proposed $63 billion buyout of Allergan. But analysts and investors were hardly impressed.